Dreamstone Partners discovers and invests in innovative Korean biotech start-ups with promising potential pipelines and looks to maximize investment return by supporting the start-ups with value-up strategy through IPO and licence-out consulting.
Our primary geographic focus is Korea, which has excellent R&D capabilities in the biotech industry ranking 4th in global patents and retains a sound biotech ecosystem, producing the number of great potential start-ups from an investment perspective.